

Table S3. Most common maintenance doses and dose frequencies by treatment for first-, second-, and third-line therapies; doses in patients with psoriatic arthritis initiating new therapy during the registry

	<u>Ustekinumab</u>	<u>Infliximab</u>	<u>Adalimumab</u>	<u>Etanercept</u>
First-Line Therapy, N	166	72	117	105
Dose	45 mg ^a	5 mg/kg	40 mg	50 ,mg
Frequency	Every 12 weeks	Every 8 weeks ^b	Every other week	Weekly ^c
n (%)	68 (41.0)	42 (58.3)	97 (82.9)	58 (55.2)
Second-Line Therapy, N	263	54	205	78
Dose	45 mg ^a	5 mg/kg	40 mg	50 mg
Frequency	Every 12 weeks	Every 8 weeks ^b	Every other week	Weekly ^c
n (%)	122 (46.4)	22 (40.7)	163 (79.5)	41 (52.6)
Third-Line Therapy, N	299	68	47	34
Dose	45 mg ^a	5 mg/kg	40 mg	50 mg
Frequency	Every 12 weeks	Every 8 weeks ^b	Every other week	Weekly ^c
n (%)	125 (41.8)	35 (51.5)	32 (68.1)	23 (67.6)

Data are reported as number of doses administered (%). N=total number of administrations for each line of therapy

^aAdditionally, a large proportion of 90-mg doses of ustekinumab every 12 weeks were administered, including 63/166 (38.0%) during first-line therapy, 75/263 (28.5) during second-line therapy, and 99/299 (33.1%) during third-line therapy.

^bInfliximab 5 mg/kg was administered every 6 weeks (3/72 [4.2%]) and at “other” dosing intervals (11/72 [15.3%]) during first-line therapy; corresponding frequencies were 8/54 (14.8%) and 12/54 (22.2%) during second-line therapy and 5/68 (7.4%) and 12/68 (17.6%) during third-line therapy.

^cA large proportion of etanercept 50-mg doses were administered twice weekly during first-line therapy (42/105 [40.0%]), during second-line therapy (31/78 [39.7%]) and during third-line therapy (8/34 [23.5%]).